At present, there are nearly a hundred enterprises working in research and development of stem cell technology, construction of stem cell banks and application of related products. In 2016, industrial scale of stem cell represented RMB46 billion.
Under the circumstances that the government energetically promotes cutting-edge medical treatment, related policies to the stem cell industry is hopeful to be gradually opened up. In 2022, the market scale of the industry is predicted to reach RMB231 billion.
Please note that this report takes 1-2 business days for delivery.
1 Development Environment of Stem Cell Industry in China
2 Development Status of Medical and Health Institutions in China, 2011-2016
2.1 Numbers of Institutions
2.2 Numbers of Beds
2.3 Numbers of Patients
2.4 Numbers of Inpatients and Discharges
2.5 Bed Utilization
3 General Development of Stem Cell Industry in China, 2011-2016
4 Analysis of Key Enterprises in China Stem Cell Industry
4.1 VCANBIO Cell & Gene Engineering Corporation, Ltd
4.2 China Cord Blood Corporation
4.3 Tianjin Amcellgene Engineering Co., Ltd.
4.4 Beijing Health-Biotech Group
4.3 Sichuan Neo-life Stem Cell Biotech Inc.
4.6 Beike Biotechnology Co., Ltd.
4.7 Shandong Qilu Stem Cell Engineering Co., Ltd.
4.8 Beijing Jiachenhong Bio-tech Corp. Ltd.
4.9 TongYuan Bio-Engineering Co., Ltd.
4.10 Shanghai Stem Cell Technology Co., Ltd.
5 Forecast and Investment Strategy of Stem Cell Industry in China, 2017-2022
5.2 Investment Strategy
5.2.1 Meaning of Strategy Planning
5.2.2 Principles of Strategy Planning
5.2.3 Analysis on Strategy Planning
5.2.4 Key Customer Strategy
List of Figures
Figure 1 China’s GDPs and growth rates, 2011-2016
Figure 2 Investments in medical treatment informatization in China, 2012-2016
Figure 3 Market scales of stem cell industry in China, 2011-2016
Figure 4 Business distribution of VCANBIO Cell & Gene Engineering Corporation, Ltd in 2016
Figure 5 Market scale forecast of stem cell industry in China, 2017-2022
List of Tables
Table 1 China’s GDP distributions, 2014-2016
Table 2 Related policies to stem cell industry in China
Table 3 Consumptions on medical and health care by urban and rural residents in China, 2012-2016
Table 4 Numbers of medical institutions in China, 2011-2016
Table 5 Numbers of beds in Chinese medical and health institutions, 2011-2016
Table 6 Numbers of patients in Chinese medical and health institution, 2011-2016
Table 7 Numbers of inpatients and discharges in Chinese medical and health institutions, 2011-2016
Table 8 Bed utilizations in Chinese hospitals, 2011-2016
Table 9 Revenues of VCANBIO Cell & Gene Engineering Corporation, Ltd by industries and products from Jan. to June in 2016
Table 10 Revenues and profits of VCANBIO Cell & Gene Engineering Corporation, Ltd, 2012-2016
Table 11 Regional revenues of VCANBIO Cell & Gene Engineering Corporation, Ltd in 2016
Table 12 Revenues of China Cord Blood Corporation, FY2012-FY2016
Table 13 Revenues and profits of Tianjin Amcellgene Engineering Co., Ltd., 2012-2015
Table 14 Operation of Beijing Health-Biotech Group, 2014-2016
Table 15 Stem cell services of Sichuan Neo-life Stem Cell Biotech Inc.
Table 16 Stem cell services of Shandong Qilu Stem Cell Engineering Co., Ltd.
Table 17 Stem cell services of Beijing Cord Blood Bank
Table 18 Administrative and Strategic Planning of Enterprises to VIPs
- Beijing Health-Biotech Group
- Beijing Jiachenhong Bio-tech Corp. Ltd.
- Beike Biotechnology Co., Ltd.
- China Cord Blood Corporation
- Shandong Qilu Stem Cell Engineering Co., Ltd.
- Shanghai Stem Cell Technology Co., Ltd.
- Sichuan Neo-life Stem Cell Biotech Inc.
- Tianjin Amcellgene Engineering Co., Ltd.
- TongYuan Bio-Engineering Co., Ltd.
- VCANBIO Cell & Gene Engineering Corporation, Ltd